scispace - formally typeset
M

Marcus Ferrone

Researcher at University of California, San Francisco

Publications -  26
Citations -  1950

Marcus Ferrone is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Curriculum & Hyperpolarized carbon-13 MRI. The author has an hindex of 16, co-authored 26 publications receiving 1725 citations.

Papers
More filters
Journal ArticleDOI

Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate

TL;DR: This first-in-man imaging study evaluated the safety and feasibility of hyperpolarized [1-13C]pyruvate as an agent for noninvasively characterizing alterations in tumor metabolism for patients with prostate cancer and showed elevated levels of lactate, alanine, and bicarbonate in regions of biopsy-proven cancer.
Journal ArticleDOI

Pancreatic Enzyme Pharmacotherapy

TL;DR: The delivery of sufficient enzyme concentrations into the duodenal lumen simultaneously with meals can reduce nutrient malabsorption, improve the symptoms of steatorrhea, and in some cases alleviate the pain associated with chronic pancreatitis.
Journal ArticleDOI

Risk of Catheter-Related Bloodstream Infection With Peripherally Inserted Central Venous Catheters Used in Hospitalized Patients

TL;DR: To determine the risk of PICC-related BSI in hospitalized patients, a prospectively studied cohort study using data from 2 randomized trials assessing the efficacy of chlorhexidine-impregnated sponge dressing and chlor hexidine for cutaneous antisepsis was conducted.
Journal ArticleDOI

Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion

TL;DR: The molecular imaging approach applied to investigate differences in perfusion and metabolism between low- and high-grade tumors in the transgenic adenocarcinoma of mouse prostate (TRAMP) transgenic mouse model of prostate cancer could be translated to investigate these imaging biomarkers for their diagnostic and prognostic power in future prostate cancer clinical trials.